Yanpeng Chu

Yanpeng Chu

Auto-generated profile, based on publicly available information

Yanpeng Chu

Department of Cardiology, Dazhou Central Hospital, Dazhou

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
Rui LiuRui Liu
Rui Liu
JLJie Liu
Jie Liu
QCQiang Cao
Qiang Cao
YCYanpeng Chu
Yanpeng Chu
HCHao Chi
Hao Chi
BLBo Li
Bo Li
Background: To explore the hub gene closely related to the progression of gastric cancer (GC), so as to provide a theoretical basis for revealing the therapeutic mechanism of GC.

21 January 2020 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
JLJie Li
Jie Li
QLQin Liu
Qin Liu
XHXuan Huang
Xuan Huang
YCYurui Cai
Yurui Cai
LSLi Song
Li Song
FZFanxin Zeng
Fanxin Zeng
C-X-C motif chemokine ligand 8 (CXCL8) is involved in tumor proliferation, migration, and invasion. However, the function of CXCL8 in colorectal cancer (CRC) is controversial. Here, we analyzed RNA-sequencing (RNA-seq) data to identify differentially expressed genes and pathways according to gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with CRC. The levels of the mRNA encoding CXCL8 were significantly increased in early and advanced stages of CRC, as well as in metastases and nonmetastasis cases using RNA-seq analysis (n = 91). These findings were consistent with immunohistochemical analysis of CXCL8 expression (n = 87). Protein-protein interaction (PPI) prediction combined with transcriptional profiling data revealed that CXCL8 levels positively correlated with cAMP responsive element binding protein 1 (CREB1)/ribosomal protein S6 kinase B1 (RPS6KB1) expression, which promotes cell proliferation and differentiation in high expression, while inversely correlated with the expression of Bcl2 associated agonist of cell death (BAD) protein to inhibit apoptosis during the progression of CRC. These findings provide compelling clinical and molecular evidence to support the conclusion that CXCL8 contributes to the genesis and progression of CRC.

5 March 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
FZFanxin Zeng
Fanxin Zeng
JFJiangping Fu
Jiangping Fu
FHFang Hu
Fang Hu
YTYani Tang
Yani Tang
XFXiangdong Fang
Xiangdong Fang
YCYanpeng Chu
Yanpeng Chu
Identification of key pathways and genes in response to trastuzumab treatment in breast cancer using bioinformatics analysis Identification of key pathways and genes in response to trastuzumab treatment in breast cancer using bioinformatics analysis

16 January 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
SZSiyang Zhao
Siyang Zhao
BZBing Zhang
Bing Zhang
CLConghai Liu
Conghai Liu
XSXiaodong Sun
Xiaodong Sun
YCYanpeng Chu
Yanpeng Chu

27 January 2025 in Clinical Cardiology
Verified
Journal Article
Open access
SYShandong Yu
Shandong Yu
WWWei Wang
Wei Wang
YGYulian Gao
Yulian Gao
JZJun Zhou
Jun Zhou
YCYanpeng Chu
Yanpeng Chu
Background: Observational studies indicate that serum urate level is associated with atrial fibrillation (AF). However, whether this association is causal remains controversial, due to confounding factors and reverse causality. We aim to evaluate the causal relationship of genetically predicted serum urate level with AF.Methods: A bidirectional Mendelian randomization (MR) study was performed. Instrumental variables were obtained from the Global Urate Genetics Consortium (110347 individuals). We obtained summary statistics of AF from two genome‐wide association studies (GWAS) data sets for AF. Inverse‐variance‐weighted method was applied to obtain MR estimates and other statistical methods were conducted in the sensitivity analyses. The reverse MR analysis was performed to evaluate the effect of AF on serum urate levels.Results: Genetically determined serum urate level was not associated with AF in two studies (OR, 1.03; 95% CI, 0.95–1.11; p = 0.47); (OR, 1.06; 95% CI, 0.99–1.12; p = 0.09). The main results kept robust in the most sensitivity analyses. Multivariable MR analyses suggested that the association pattern did not change, after adjusting for body mass index (BMI), HbA1c: hemoglobin A1c (HbA1c), hypertension, low‐density lipoprotein cholesterol (LDL‐C) and coronary heart disease. No causal effect of AF on serum urate levels was found in two studies (OR, 1.02; 95% CI, 0.98–1.05; p = 0.30); (OR, 1.00; 95% CI, 0.98–1.03; p = 0.95).Conclusions: Our MR study supports no bidirectional causal effect of serum urate levels and AF. This implies that treatments aimed at lowering uric acid may not reduce the risk of AF.

14 August 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
QHQian Huang
Qian Huang
LZLi Yi Zhang
Li Yi Zhang
HSHui Lin Shu
Hui Lin Shu
NCNa Chen
Na Chen
RLRong Hua Li
Rong Hua Li
YCYan Peng Chu
Yan Peng Chu
As the fourth most common malignancy among women globally, cervical cancer is intimately linked to persistent high-risk human papillomavirus (HPV) infection; however, HPV infection is not the sole pathogenic factor. Recent studies have revealed that the composition, dynamics, and metabolic products of the vaginal microbiota play pivotal roles in the occurrence, progression, diagnosis, and treatment of cervical cancer. This article offers a comprehensive narrative review of foundational research on the vaginal microbiome in cervical cancer patients, correlations with metabolites, epidemiological characteristics, diagnostic applications, therapeutic strategies, and ongoing controversies and challenges. Basic research demonstrates that increased vaginal microbial diversity and reduced Lactobacillus abundance are associated with cervical cancer progression, wherein pathogenic bacteria such as Fusobacterium spp. and Sneathia spp. have been associated with tumorigenesis through immunosuppression and inflammatory mechanisms. Metabolites like 3-hydroxybutyrate and sphingolipids show potential as diagnostic biomarkers and therapeutic targets. Epidemiological studies reveal associations between variations in the vaginal microbiota across different populations (e.g., African, Latina) and cervical cancer risk. In diagnostics, detection methods based on the vaginal microbiome can enhance early screening efficiency, with novel sequencing technologies combined with artificial intelligence demonstrating promising application prospects. Therapeutically, interventions such as probiotics and microbiota modulation may improve patient outcomes. Nonetheless, current research faces challenges, including an unclear causal relationship between the microbiota and HPV infection and a lack of standardization in detection techniques. Future endeavors necessitate multi-omics integration, large-scale longitudinal studies, and precise intervention strategies to facilitate the clinical translation of vaginal microbiome research into cervical cancer prevention and treatment.